Positive News SentimentPositive NewsNASDAQ:URGN UroGen Pharma (URGN) Stock Forecast, Price & News $11.35 +0.29 (+2.62%) (As of 02:02 PM ET) Add Compare Share Share Today's Range$10.78▼$11.4250-Day Range$8.75▼$14.2952-Week Range$6.05▼$16.11Volume81,249 shsAverage Volume152,344 shsMarket Capitalization$258.10 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside50.1% Upside$16.50 Price TargetShort InterestBearish4.80% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.34) to ($3.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector345th out of 986 stocksPharmaceutical Preparations Industry154th out of 481 stocks 3.3 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, UroGen Pharma has a forecasted upside of 50.1% from its current price of $10.99.Amount of Analyst CoverageUroGen Pharma has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.80% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in UroGen Pharma has recently increased by 29.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 2.5 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for UroGen Pharma this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders12.80% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.90% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($4.34) to ($3.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About UroGen Pharma (NASDAQ:URGN) StockUroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.Read More Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesMay 22, 2023 | finance.yahoo.comWith 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big gunsMay 19, 2023 | americanbankingnews.comUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q2 2023 Earnings of ($1.14) Per Share, HC Wainwright ForecastsJune 9, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 16, 2023 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call TranscriptMay 15, 2023 | msn.comOppenheimer Reiterates UroGen Pharma (URGN) Outperform RecommendationMay 12, 2023 | msn.comRecap: UroGen Pharma Q1 EarningsMay 11, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Hold Rating on Urogen Pharma (URGN)May 11, 2023 | finance.yahoo.comUrogen Pharma (URGN) Reports Q1 Loss, Tops Revenue EstimatesJune 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...May 11, 2023 | finance.yahoo.comUroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsMay 10, 2023 | americanbankingnews.comUroGen Pharma (URGN) Set to Announce Quarterly Earnings on ThursdayMay 4, 2023 | finance.yahoo.comUroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023May 2, 2023 | finance.yahoo.comEarnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to DeclineMay 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Urogen Pharma (URGN)May 1, 2023 | finance.yahoo.comFirst Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic EvaluationApril 30, 2023 | finance.yahoo.comNew Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal PelvisApril 29, 2023 | americanbankingnews.comUroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Up 16.3% in AprilApril 25, 2023 | finance.yahoo.comUroGen Pharma to Present at H.C. Wainwright BioConnect ConferenceApril 18, 2023 | finance.yahoo.comUroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift SharesApril 14, 2023 | americanbankingnews.comHC Wainwright Comments on UroGen Pharma Ltd.'s Q1 2023 Earnings (NASDAQ:URGN)April 13, 2023 | americanbankingnews.comUroGen Pharma Ltd. to Post Q1 2024 Earnings of ($0.80) Per Share, HC Wainwright Forecasts (NASDAQ:URGN)April 11, 2023 | msn.comHC Wainwright & Co. Reiterates Urogen Pharma (URGN) Buy RecommendationApril 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Urogen Pharma (URGN)April 1, 2023 | americanbankingnews.comResearch Analysts Set Expectations for UroGen Pharma Ltd.'s FY2027 Earnings (NASDAQ:URGN)March 31, 2023 | americanbankingnews.comQ1 2023 Earnings Estimate for UroGen Pharma Ltd. Issued By Oppenheimer (NASDAQ:URGN)March 18, 2023 | seekingalpha.comUroGen Pharma Ltd. (URGN) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call TranscriptSee More Headlines URGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart URGN Company Calendar Last Earnings3/16/2023Today6/09/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees195Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$23.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+49.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,780,000.00 Net Margins-163.25% Pretax Margin-162.02% Return on EquityN/A Return on Assets-84.85% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.59 Sales & Book Value Annual Sales$64.36 million Price / Sales3.91 Cash FlowN/A Price / Cash FlowN/A Book Value($3.93) per share Price / Book-2.81Miscellaneous Outstanding Shares22,740,000Free Float19,830,000Market Cap$251.50 million OptionableOptionable Beta0.75 Key ExecutivesElizabeth BarrettPresident, Chief Executive Officer & DirectorDong KimChief Financial & Accounting OfficerMarina KonortyExecutive Vice President-Research & DevelopmentMark P. SchoenbergChief Medical OfficerMoran MieronDirector-Research & Pre-Clinical AffairsKey CompetitorsEagle PharmaceuticalsNASDAQ:EGRXVerrica PharmaceuticalsNASDAQ:VRCANkartaNASDAQ:NKTXKamadaNASDAQ:KMDANewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 59,695 shares on 5/18/2023Ownership: 0.266%State Street CorpBought 7,632 shares on 5/16/2023Ownership: 0.529%Jane Street Group LLCBought 84,870 shares on 5/16/2023Ownership: 0.373%Great Point Partners LLCSold 520,778 shares on 5/16/2023Ownership: 0.172%Boothbay Fund Management LLCBought 1,936 shares on 5/15/2023Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions URGN Stock - Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares. View URGN analyst ratings or view top-rated stocks. What is UroGen Pharma's stock price forecast for 2023? 2 analysts have issued twelve-month price objectives for UroGen Pharma's shares. Their URGN share price forecasts range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 49.2% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts. How have URGN shares performed in 2023? UroGen Pharma's stock was trading at $8.87 on January 1st, 2023. Since then, URGN stock has increased by 24.7% and is now trading at $11.06. View the best growth stocks for 2023 here. Are investors shorting UroGen Pharma? UroGen Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 944,700 shares, an increase of 29.3% from the April 30th total of 730,500 shares. Based on an average daily volume of 175,400 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.8% of the company's shares are sold short. View UroGen Pharma's Short Interest. When is UroGen Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our URGN earnings forecast. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.10. The business earned $18.09 million during the quarter, compared to analysts' expectations of $18.25 million. What ETF holds UroGen Pharma's stock ? ARK Israel Innovative Technology ETF holds 269,775 shares of URGN stock, representing 2.49% of its portfolio. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. What is UroGen Pharma's stock symbol? UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN." Who are UroGen Pharma's major shareholders? UroGen Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.08%), BlackRock Inc. (1.25%), ARK Investment Management LLC (1.19%), Bank of America Corp DE (0.57%), State Street Corp (0.53%) and Meitav Investment House Ltd. (0.47%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson and Peter P Pfreundschuh. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is UroGen Pharma's stock price today? One share of URGN stock can currently be purchased for approximately $11.06. How much money does UroGen Pharma make? UroGen Pharma (NASDAQ:URGN) has a market capitalization of $251.50 million and generates $64.36 million in revenue each year. The company earns $-109,780,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis. How many employees does UroGen Pharma have? The company employs 195 workers across the globe. How can I contact UroGen Pharma? UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com. This page (NASDAQ:URGN) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.